Achaogen, Inc. announced a collaboration with CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator). CARB-X selected Achaogen from a group of 368 companies and research groups worldwide to be a recipient of the award to support the development of its new class of antibiotic designed to inhibit LpxC. Achaogen was awarded $3.2 million over 12 months, and potentially up to a total award of $11.4 million after that period upon achievement of certain milestones. LpxC is an essential enzyme unique to gram-negative bacteria.